Clinical trial NCT01265836: Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes
Official title: Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Dyslipidemia
Keywords: Dyslipidemia Treatment and Cardiovascular Outcomes
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2010-12-23
Enrollment: 1064
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. Provision of subject informed consent
2. Female or male aged = 18 years
3. Patients eligible for treatment of dyslipidemia with statins, according to the current guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention.
4. Receiving lipid-lowering drug treatment for at least 15 days.

Brief summary: The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment (statin or combination) reaching the LDL-C goals according to the updated 2004 National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines.

Detailed description: MC MD

Eligibility criteria: Inclusion Criteria:

* Provision of subject informed consent, Female or male aged = 18 years
* Patients eligible for treatment of dyslipidemia with statins, according to the current guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention Receiving lipid-lowering drug treatment for at least 15 days.

Exclusion Criteria:

* Involvement in the planning and conduct of the study (applies to either AstraZeneca staff or staff at the study site).
* Previous enrolment or randomisation of treatment in the present study
* Participation in a clinical study during the last 90 days

Primary outcomes:
measure: The number (#) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines.
timeFrame: 1 year
measure: The percent (%) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines.
timeFrame: 1 year
Secondary outcomes:
measure: The number of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets
timeFrame: 1 year
measure: The number of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1
timeFrame: 1 year
measure: The number of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year
timeFrame: 1 year
measure: The percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets
timeFrame: 1 year
measure: The percent of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1
timeFrame: 1 year
measure: The percent of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
affiliation: Maharaj Nakorn Chiangmai Hospital Cardiovascular division, Department of Internal Medicine, Faculty of Medicine, Chiangmai University
name: Apichard Sukonthasarn, Prof.M.D.
role: PRINCIPAL_INVESTIGATOR
References: